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Summary: We investigated a one-step immunometric CA 125 assay, which employs new anti-CA 125 antibodies
as capture antibodies and OC125 antibodies for detection, for interference due to antibodies induced by
repeated administration of F(ab')2 fragments of the anti-CA 125 antibody OC125. Testing 33 samples, obtained
from 13 patients treated with OC125 fragments, we found falsely high CA 125 concentrations only in samples
with exceptionally high concentrations of both anti-idiotypic antibodies and non-specific human anti-mouse
antibodies. In contrast, the recovery of added CA 125 was already diminished in the presence of low anti-
idiotypic antibody concentrations. Both interferences disappeared after removal of serum IgG. It was possible
to eliminate the falsely high results, but not the reduction in recovery rate, by adding non-specific murine
IgG. When the binding of the detector antibodies was performed in a separate incubation step, no reduction
in recovery rate was observed. Our results suggest that non-specific human anti-mouse antibodies are
responsible for falsely high results. The reduction in the recovery rate is obviously due to an inhibition of the
binding of OC125 detector antibodies by anti-idiotypic antibodies. In patients receiving OC125 antibodies
CA 125 can be measured using OC125 detector antibodies if a two-step assay is performed. An increase in
CA 125 following OC125 infusion should be confirmed after the addition of non-specific murine IgG.
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One effect of in vivo application of OC125 F(ab')2 in samples with elevated concentrations of anti-idio-
fragments is the induction of antibody formation (8). typic antibodies (11, 12). Our results suggested that
In a previous investigation we demonstrated that depending on the test protocol, anti-idiotypic and-
among the antibodies directed against epitopes com- bodies can reduce the assay response resulting in
mon to all murine antibodies, anti-idiotypic antibod- falsely low values for CA 125, especially when OC125
ies directed against the hypervariable region of the antibodies are used for detection.
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In the present study we investigated an immunometric
test for CA 125 that involves a newly developed anti-
CA 125 antibody on the solid phase and I25I-labelled
OC125 antibodies for detection, for interferences due
to antibodies formed after treatment with OC125
fragments. Furthermore, the mechanisms of the ob-
served interferences were investigated.
OC125 antibodies are used as both the immobilized and the
labelled antibodies, anti-idiotypic antibodies directed against
idiotypes of the OC125 can simulate the presence of antigen by
cross-linking capture and detector antibodies (9, 10). Thus, in
samples with low CA 125 concentrations the results of the CA
125 El A almost exclusively reflect the'dffect of the anti-idiotypic
antibodies. The test was performed according to the manufac-
turers' instructions. The concentration of anti-idiotypic anti-
bodies was expressed, as is CA 125, in arb. U/l.
Materials and Methods
Pa t i en t sand serum samples
All serum samples investigated were obtained routinely during
follow-up of ovarian cancer patients (Stage II —IV FIGO). The
samples were aliquoted and stored at — 20 °C until analysis.
Thirty and three samples were drawn from 13 patients who
had received one or more infusions of 1 mg 131I-labelled F(ab')2
fragments of the anti-CA 125 antibody OC125 (IMACIS-2;
Isotopen Diagnostik CIS, Dreieich, Germany) for
radioimmunodetection. Two control samples were obtained
from two other ovarian cancer patients not yet treated with
OC125 antibodies.
Determinat ion of CA 125
CA 125 was measured with the ELSA-CA 125 II (Isotopen
Diagnostik CIS, Dreieich, Germany), a solid-phase immuno-
metric assay employing a newly developed murine monoclonal
anti-CA 125 antibody as capture antibody. OC125 antibodies
serve only as I25l-labelled detector antibodies. According to the
normal test protocol proposed by the manufacturers, the bind-
ing of both antibodies takes place simultaneously during one
incubation step: 0.1 ml of the samples were incubated together
with 0.3 ml of radioiodinated OC125 antibodies in test tubes
coated with anti-CA 125 capture antibodies (20 h, room tem-
perature). After the incubation the tubes were washed and the
bound radioactivity was measured.
In some cases we performed a modified two-step test in order
to exclude the possibility that serum components not bound to
the solid phase might interfere with the binding of detector
antibodies: in the first step 0.1 ml of sample were incubated
(20 h, room temperature) with the immobilized capture anti-
bodies together with 0.3 ml of zero standard (provided with
the ELSA-CA 125 II test kit) supplemented with 0.1 g/1 of non-
specific murine IgG (Calbiochem Novabiochem, Bad Soden,
Germany). After the incubation the tubes were washed to
remove all serum components not bound to the solid phase. In
the second step 0.3 ml of radioiodinated OC125 antibodies were
incubated (20 h, room temperature) with 0.1 ml of zero stan-
dard. After a further wash the bound radioactivity was meas-
ured. If not otherwise indicated the test was performed accord-
ing to the normal test protocol.
Recovery of CA 125
In order to identify inhibitory agents in serum samples we
determined the recovery of a known amount of CA 125 added
to the native serum: 0.01 ml of a serum pool from an ovarian
cancer patient with a CA 125 concentration of 5000 χ ΙΟ3 arb.
U/l were added to 0.24 ml of sample and the resulting CA 125
concentration was measured with the ELSA-CA 125 II. Recov-
ery was expressed as fraction of the amount added.
Determinat ion of ant i - idiotypic antibodies
Anti-idiotypic antibodies were determined with the Abbott CA
125 El A monoclonal. Since in this immunometric test the
Determination of non-specific human anti-mouse
antibodies
Non-specific anti-mouse antibodies (anti-iso/allotypic antibod-
ies) were determined with the ImrmiSTRIP HAMA-EIA (Irn-
munomedics Inc., Newark, NJ) as previously described (9).
Removal of interfering IgG from serum samples
Interfering IgG were removed by affinity chromatography on
Protein G-Sepharose (Pharmacia, Freiburg, Germany). We ap-
plied 1 ml of serum sample diluted 2-fold with phosphate buffer
(0.2 mol sodium phosphate and 10 g bovine serum albumin per
litre, pH 7.0) to the 2,5 ml column equilibrated with phosphate
buffer. After a 5-min incubation at room temperature, the
column was washed with 8 ml of phosphate buffer to elute the
unadsorbed fraction. The complete wash fraction was frozen
immediately at -^80°C and subsequently lyophilized. At the
time of further use the IgG-free samples were reconstituted with
1 ml of distilled water. The absorbed IgG fraction was eluted
with 4 ml of elution buffer (1 mol/1 glycine HC1 buffer, pH 2.8),
after a further wash with 5 ml of phosphate buffer. The eluate
was neutralized immediately with 0.4 ml of neutralizing buffer
(1 mol/1 sodium phosphate, pH 8.0), frozen at — 80 °C and
lyophilized. At the time of further use the IgG fractions were
reconstituted with 1 ml of distilled water.
Blocking of non-specific human anti-mouse
antibodies
To block anti-iso/allotypic antibodies non-specific murine IgG
(Calbiochem Novabiochem, Bad Soden, Germany) were added
to the native serum samples. Murine IgG solution (0.01 ml)
(16.6 g/1) was added to 0.24 ml of sample.
Results
Falsely high CA 125 values
In 33 serum samples, obtained from 13 patients after
treatment with OC125 fragments, we determined the
apparent CA 125 concentration with the ELSA-CA
125 II. While the real CA 125 concentrations deter-
mined after removal of interfering IgG iri all samples
were lower than 30 χ ΙΟ3 arb. U/l, in 7 native sanu
pies, with elevated concentrations of both anti-idio-
typic antibodies (8 400 -1 552 000 χ l O3 arb. U/l) and
non-specific human anti-mouse antibodies (965^-
18 800 μg/l), we measured falsely high CA 125 values
up to 126 χ 103 arb. U/l. It was possible to reduce
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the falsely high Ca 125 values by addition of non-
specific murine IgG. In 4 samples with falsely high
results the apparent CA 125 concentrations were re-
duced to values lower than 10 χ ΙΟ3 arb. U/l after
addition of 0.66 g/1 murine IgG. The CA 125 concen-
trations measured with the ELSA-CA 125 II in two
control samples were not influenced by the addition
of murine IgG (tab. 1).
Tab. 1. Effect of addition of non-specific murine IgG on falsely
high CA 125 results measured with the ELSA-CA 125
II in 4 samples with elevated concentrations of anti-
idiotypic antibodies and non-specific human anti-
mouse antibodies (HAMA), and on the CA 125 con-
centration of 2 controls.
Sample
no.
3844*
4177*
1549
2203
2835
3621
Anti-idiotypic HAMA
antibodies
[103 arb. U/l] foig/l]
n.d.**
n.d.**
8442
196000
416000
1552000
<60
<60
965
11000
7600
18800
Apparent CA 125
[103 arb. U/l]
Native + Murine Ig
328
140
74
38
89
61
318
141
6
n.d.**
n.d.**
10
* control samples
** not detected
Falsely low CA 125 values
Figure 1 shows the extent of recovery of added Ca
125 from 25 samples obtained from 13 patients using
two different test protocols. When CA 125 was de-
termined with the ELSA-CA 125 II according to the
normal test protocol, the recovery of CA 125 was
diminished in the presence of anti-idiotypic antibodies
in a concentration-dependent manner. From samples
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Fig. 1. Relationship between the concentration of anti-idiotypic
antibodies and the extent of recovery of added CA 125,
measured with the ELSA-CA 125 II according to the
normal one-step (·) and the modified two-step (D) test
protocol, from 25 serum samples obtained from' 13
patients after OC125 treatment.
with anti-idiotypic antibody concentrations exceeding
5000 χ 103 arb. U/l less than 20% of the added CA
125 was recovered. When binding of the detector
antibodies was performed in a separate incubation
step according to the modified test protocol, the CA
125 recovery was quite good. Further, from samples
with anti-idiotypic antibody concentrations exceeding
5000 χ 103 arb. U/l the CA 125 was recovered com-
pletely.
In 5 samples with reduced recovery rates we removed
serum IgG by means of chromatography on protein
G sepharose. After IgG removal, the added CA 125
was recovered nearly completely from all samples,
whereas from the IgG-containing elution fraction of
the protein G column the recovery was diminished
(fig. 2).
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Fig. 2. Relationship between the concentration of anti-idiotypic
antibodies and the extent of recovery of added CA 125
from 5 serum samples after IgG removal with protein
G (n) and from the IgG-containing eluate of the protein
G column (D).
Non-specific murine IgG were added to another 5
samples with reduced recovery rates to block putative
activity of non-specific human anti-mouse antibodies.
The recovery rates were not influenced by the addition
of (0.66 g/1) murine IgG (tab. 2).
Tab. 2. Effect of addition of non-specific murine IgG on the
reduced recovery rates measured with the ELSA-CA
125II in 5 samples with elevated concentrations of anti-
idiotypic antibodies.
Samples
no.
5179
1717
2029
1602
3402
Anti-idiotypic
antibodies
[ΙΟ3 arb. U/l]
3225
4115
4843
7343
16627
% Recovery
of added CA 125
Native + Murine Ig
24 23
16 13
23 27
0 1
5 0
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Discussion
The present results confirm that anti-idiotypic anti-
bodies formed after repeated administration of OC125
fragments do not bind to the capture antibodies used
in the ELSA-CA 125 II. Thus, falsely high values, as
observed with a homologous assay involving OC125
antibodies as both the immobilized and the labelled
antibodies (9), cannot occur in this test. Falsely high
values were only observed in serum samples with very
high concentrations of anti-idiotypic antibodies and
non-specific human anti-mouse antibodies. Such in-
terference was eliminated by IgG removal, indicating
that the responsible agents were human serum IgG.
In a previous study we observed similar effects with
two other immunometric assays for CA 125 which
also employ no OC125 antibodies on the solid phase
(11). We assume that such interference may be due-to
non-specific human anti-mouse antibodies formed af-
ter treatmerirwith OC125 fragments, which simulate
the presence of antigen by crosslinking capture and
detector antibodies. Interference by non-specific hu-
man anti-mouse antibodies has been reported for sev-
eral immunometric assays (13 — 16). Thus, as with the
ELSA-CA 125 II we used in this study, most imrnu-
noassays include non-specific murine immunoglobu-
lins to block the activity of non-specific human anti-
mouse antibodies (14, 15, 17). However, as demon-
strated by Boscato & Stuart (18), in samples with very
high concentrations of non-specific human anti-
mouse antibodies the amount of murine immuno-
globulin added to an assay system may not always be
enough to prevent interference. Falsely high results in
the ELSA-CA 125 II may be due to non-specific
human anti-mouse antibodies not further blocked by
murine immunoglobulins. This hypothesis is sup-
ported by the fact that it was possible to block inter-
ference by the addition of murine IgG.
A more prominent interference observed with the
ELSA-CA 125 II is the reduction of assay response,
which is evident in recovery studies. The negative
correlation between the extent of recovery and the
concentration of anti-idiotypic antibodies and the fact
that the inhibitory agents were absorbed by protein
G and were recovered in the IgG-containing eluate,
suggest that the responsible agents were human serum
IgG formed together with the anti-idiotypic antibod-
ies after treatment with OC125 fragments. Reduction
of assay response can be produced by high concen-
trations of non-specific human antirinouse antibodies,
presumably due to the inhibition of antigen-binding
to reagent antibodies (18, 19). However, the effect
observed with the ELSA-CA 125II cannot be ascribed
to non-specific human anti-mouse antibodies because
it could not be blocked by murine IgG. The fact that
no interference occurred in the modified two-step test
version indicates that interfering agents react with the
OC125 detector antibodies used in the test studied.
Thus, the results support the hypothesis that the re-
duction of assay response is due to anti-idiotypic
antibodies that mask the OC125 detector antibodies
and prevent the binding of CA 125. This is also in
accordance with the fact that we observed no reduc-
tion of assay results in the presence of aiiti-idiotypic
antibodies with another two-step immunometric CA
125 assay using OC125 antibodies for detection (12).
The use of test kits involving no OC125 antibodies as
capture antibodies cannot completely eliminate inter-
ference by antibodies newly formed after the treat-
ment with OC125 fragments. Even with these tests
falsely high results can occur, due presumably to high
concentrations of non-specific human anti-mouse an-
tibodies. Thus, increased CA 125 values following
OC125 application should be confirmed after addition
of non-specific murine IgG. To avoid falsely low re-
sults, assays involving OC125 antibodies for detection
should be performed in a two-step protocol.
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